Congestive heart failure: guidelines for the primary care physician
Related Experiment Video
Updated: Sep 20, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
1Zena and Michael A. Wiener Cardiovascular Institute, Box 1030, Mount Sinai School of Medicine, One East 100th Street, New York, NY 10029, USA.
Insights
Heart failure affects millions annually, costing billions. This review examines treatments like ACE inhibitors and beta blockers to improve patient outcomes and reduce disease progression.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure impacts nearly 5 million Americans yearly, with 500,000 new diagnoses.
- The disease incurs substantial societal and healthcare costs, estimated at $40 billion annually.
- Medications for heart failure alone account for approximately $500 million in annual spending.
Framework:
- Review of current treatment strategies for heart failure.
- Utilizes a patient case study to illustrate treatment application.
- Focuses on evidence-based data for medication efficacy.
Implementation:
- Discusses angiotensin-converting enzyme inhibitors (ACE inhibitors).
- Covers angiotensin receptor blockers (ARBs).
- Includes diuretics, digoxin, beta blockers, and spironolactone.
Implications:
- Aims to improve disease prevention and slow progression.
- Seeks to decrease morbidity and mortality rates.
- Focuses on optimizing patient quality of life through effective management.
Abstract:
Heart failure is a common medical condition affecting nearly 5 million people each year in the United States, of whom 500,000 are newly diagnosed. The impact of this disease on society and the health care system is immense. Inpatient and outpatient costs are approximately $40 billion annually, almost $500 million of which is spent on heart failure medications alone. Beyond the problem of financial costs, however, it is imperative for us as health care professionals to improve our ability to prevent disease progression, decrease morbidity and mortality, and optimize patients quality of life. The use of a broad spectrum of treatments is reviewed in the context of a patient case study. Primary data justifying the use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics, digoxin, as well as beta blockers and spironolactone, is reviewed, with special reference to the stage of heart failure.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VII: Nursing Interventions
Cardiomyopathy V: Interprofessional Care
Rheumatic Heart Disease III: Medical Management
Cardiomyopathy VI: Nursing Management
Heart Failure VI: Adjunct Therapies
